Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_3
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

recruiting125%
active_not_recruiting125%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_3

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109
active_not_recruitingphase_3

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892
completedphase_3

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04886596
completedphase_3

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

NCT05568797

Clinical Trials (4)

Showing 4 of 4 trials
NCT07220109Phase 3

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

Recruiting
NCT06534892Phase 3

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Active Not Recruiting
NCT04886596Phase 3

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Completed
NCT05568797Phase 3

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4